NASDAQ:TLIS Talis Biomedical (TLIS) Stock Price, News & Analysis $1.70 +0.20 (+13.33%) As of 09/4/2025 01:55 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Talis Biomedical Stock (NASDAQ:TLIS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Talis Biomedical alerts:Sign Up Key Stats Today's Range$1.70▼$1.7050-Day Range$1.25▼$1.7052-Week Range$1.04▼$2.20Volume421 shsAverage Volume2,172 shsMarket Capitalization$3.10 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois. Read More Talis Biomedical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreTLIS MarketRank™: Talis Biomedical scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Talis Biomedical. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Talis Biomedical is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Talis Biomedical is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTalis Biomedical has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.30% of the outstanding shares of Talis Biomedical have been sold short.Short Interest Ratio / Days to CoverTalis Biomedical has a short interest ratio ("days to cover") of 9.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTalis Biomedical does not currently pay a dividend.Dividend GrowthTalis Biomedical does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.30% of the outstanding shares of Talis Biomedical have been sold short.Short Interest Ratio / Days to CoverTalis Biomedical has a short interest ratio ("days to cover") of 9.Change versus previous month News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Talis Biomedical this week, compared to 0 articles on an average week. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Talis Biomedical insiders have not sold or bought any company stock.Percentage Held by Insiders46.00% of the stock of Talis Biomedical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.77% of the stock of Talis Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Talis Biomedical's insider trading history. Receive TLIS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Talis Biomedical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TLIS Stock News HeadlinesTalis Biomedical (NASDAQ:TLIS) Trading 13.3% Higher - Here's What HappenedSeptember 5 at 4:01 AM | americanbankingnews.comBaker Bros. Advisors LP's Strategic Acquisition in Talis Biomedical CorpOctober 10, 2024 | finance.yahoo.com6-Figure Target for BTC by 2025Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really investing in this coin. | Crypto 101 Media (Ad)Talis Biomedical Corp Ordinary SharesSeptember 17, 2024 | morningstar.comMTalis Biomedical Shares Fall on Bankruptcy Filing, Delisting NoticeAugust 24, 2024 | marketwatch.comTLIS Stock Earnings: Talis Biomedical Reported Results for Q2 2024August 19, 2024 | investorplace.comTalis Biomedical Shares Tumble Premarket as Company Mulls BankruptcyAugust 7, 2024 | marketwatch.comWhy Talis Biomedical (TLIS) Stock Is Getting Obliterated TodayAugust 7, 2024 | benzinga.comSee More Headlines TLIS Stock Analysis - Frequently Asked Questions How have TLIS shares performed this year? Talis Biomedical's stock was trading at $1.7590 at the beginning of the year. Since then, TLIS stock has decreased by 3.4% and is now trading at $1.70. How were Talis Biomedical's earnings last quarter? Talis Biomedical Co. (NASDAQ:TLIS) announced its earnings results on Tuesday, March, 15th. The company reported ($18.90) EPS for the quarter, topping the consensus estimate of ($19.20) by $0.30. When did Talis Biomedical's stock split? Talis Biomedical's stock reverse split on Thursday, July 6th 2023.The 1-15 reverse split was announced on Thursday, July 6th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Talis Biomedical IPO? Talis Biomedical (TLIS) raised $150 million in an initial public offering (IPO) on Friday, February 12th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Piper Sandler acted as the underwriters for the IPO and BTIG was co-manager. How do I buy shares of Talis Biomedical? Shares of TLIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Talis Biomedical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Talis Biomedical investors own include Bloom Energy (BE), SoFi Technologies (SOFI), Athenex (ATNX), Alkaline Water (WTER), Milestone Scientific (MLSS), TherapeuticsMD (TXMD) and Affirm (AFRM). Company Calendar Last Earnings3/15/2022Today9/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:TLIS CIK1584751 Webtalis.bio Phone650-433-3000FaxN/AEmployees260Year FoundedN/AProfitability EPS (Trailing Twelve Months)($28.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$62.01 million Net MarginsN/A Pretax Margin-12,506.37% Return on Equity-79.74% Return on Assets-57.16% Debt Debt-to-Equity RatioN/A Current Ratio7.76 Quick Ratio7.76 Sales & Book Value Annual Sales$300 thousand Price / Sales10.33 Cash FlowN/A Price / Cash FlowN/A Book Value$37.95 per share Price / Book0.04Miscellaneous Outstanding Shares1,823,000Free Float984,000Market Cap$3.10 million OptionableNo Data Beta1.30 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:TLIS) was last updated on 9/6/2025 by MarketBeat.com Staff From Our Partners6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett's Strangest AI InvestmentTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredOdd trade could help investors secure their wealth in 2025The most profitable phrase you’ve never heard of... Have you heard of 310F? This simple string of code coul...Eagle Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talis Biomedical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talis Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.